GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c00367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Yecheng Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325000, China. Hauptthemen laut MEDLINE: Von Hippel-Lindau Tumor Suppressor Protein, Transcription Factors, Ubiquitin-Protein Ligases, Cell Cycle Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Despite the identification of over 600 E3 ligases, current proteolysis-targeting chimeras (PROTACs) predominantly rely on CRBN and VHL. Recently, GID4, a substrate receptor of the CTLH E3 ligase complex, emerged as a promising alternative handle. Herein, through structural simplification of a known GID4 ligand, we developed compound a11 as a potent GID4-recruiting BRD4 degrader. Compound a11 induced efficient, selective, and GID4-dependent BRD4 degradation via the ubiquitin-proteasome pathway (DC50 = 0.21 ± 0.04 μM). Crucially, a11 maintained degradation activity in VHL- and CRBN-deficient models, exhibiting superior antiproliferative effects in VHL-deficient 786-O renal cell carcinoma (RCC) cells. In vivo, a11 achieved significant tumor growth inhibition (TGI = 67%) in a 786-O xenograft model, outperforming corresponding CRBN- and VHL-recruiting analogs. This platform's broader utility was further confirmed by successfully degrading VEGFR2. Overall, this study establishes GID4 as a viable PROTAC handle with therapeutic potential in renal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325000, China.
- The Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Second Military Medical University (Naval Medical University), 325 Guohe Road, Shanghai 200433, China.
- School of Pharmacy, Wannan Medical University, Wuhu 241002, China.
- Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China.
ORCID-Profile: Chunquan Sheng, Guoqiang Dong
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Tang, Y., Zhang, M., Fang, Y., Li, Q., Song, Y., Sheng, C., & Dong, G. (2026). GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c00367
Vancouver
Tang Y, Zhang M, Fang Y, Li Q, Song Y, Sheng C, et al. GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c00367
BibTeX
@article{Tang2026,
author = {Tang, Yecheng and Zhang, Mingming and Fang, Yuxin and Li, Qingjun and Song, Yingqi and Sheng, Chunquan and Dong, Guoqiang},
title = {GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c00367}
}
EUVIMED